Teva inhaler approved; Oxford to create center for drug delivery devices;

> Teva ($TEVA) received FDA approval for its Qvar inhaler with a dose counter to treat asthma. Release

> Oxford University announced plans for a new research center, The Oxford Centre for Drug Delivery Devices. Release

> Equashield announced FDA clearance of its eponymous first and second generation closed systems to minimize exposure to hazardous drugs. Release

> FDA agreed to review Mallinckrodt's ($MNK) New Drug Application for its extended-release oral formulation of hydrocodone and acetaminophen for pain management. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.